Accessibility StatementSkip Navigation ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative disorders, and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), a clinical-stage cell therapy company developing treatments for neurodegenerative diseases and diabetes today announced that the ITOL-102 cell therapy program for Type 1 Diabetes, originally ...

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango TherapeuticsTango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using ...

Oct 29, 2025 6:30 AM Eastern Daylight Time Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors Share LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Dr. Jeffrey Jonas to its Board of Directors, effective immediately. Dr. Jonas brings more than three decades of leadership in pharmaceutical research and development, with a par ...

Core Insights - Immunic, Inc. is a biotechnology company focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases [1] - The lead development program, vidofludimus calcium (IMU-838), is in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026 [1] - The company is participating in several industry and investor conferences in November, including BIO-Europe and the Jefferies Global Healthcare Conference [3] Company Overview - Immunic, Inc. is listed on Nasdaq under the ticker IMUX and specializes in therapies for chronic inflammatory and autoimmune diseases [1] - Vidofludimus calcium acts as a first-in-class nuclear receptor-related 1 (Nurr1) activator and selectively inhibits dihydroorotate dehydrogenase (DHODH) [1] - Other development programs include IMU-856, targeting Sirtuin 6 (SIRT6) for gastrointestinal diseases, and IMU-381, currently in preclinical testing [1] Clinical Development - Vidofludimus calcium has shown therapeutic activity in phase 2 trials for relapsing-remitting and progressive multiple sclerosis [1] - IMU-856 aims to restore intestinal barrier function and could be applicable in various gastrointestinal diseases [1] - IMU-381 is being developed to address specific needs in gastrointestinal diseases and is currently in preclinical testing [1]

Accessibility StatementSkip Navigation The new CUSIP number for the Common Shares following the Merger and the Reverse Split will be H5835A109. A notice of the Reverse Split and other capital measures approved by the Company in connection with the Merger and the Reverse Split, will be filed with the commercial registry of the Canton of Zurich, Switzerland, on October 30, 2025. As a result, the Reverse Split will become effective in Switzerland on October 30, 2025, and will be reflected on Nasdaq at market o ...

Core Insights - In September, the OTC market in the U.S. welcomed 30 new companies, a decrease of 9 compared to the previous month [1] - There were 5 companies that transitioned from OTC to the main board, an increase of 3 from August [1] - The new listings came from 6 countries, with Canada accounting for 47% of the new companies [1] - As of September 30, 2025, there are 12,278 companies listed on the U.S. OTC market, with a transaction volume of $61.2 billion for the month and $527.1 billion year-to-date [1] New Listings - The following companies were newly listed in September: - EMPIRE METALS LTD (OTCQX: EPMLF) - VERUSA HOLDING A S (OTCQX: VRSHF) - ACG Metals Limited (OTCQX: ACGAF) - FIRST NORDIC METALS CORP. (OTCQX: FNMCF) - Bitcoin Treasury Corporation (OTCQX: BTCFF) - Radisson Mining Resources Inc. (OTCQX: RMRDF) - Bonvenu Bancorp, Inc. (OTCQX: BBNA) - Associated Capital Group, Inc. (OTCQX: ACGP) - Horizon Kinetics Holding Corporation (OTCQX: HKHC) - Capstone Green Energy Holdings Inc. (OTCQX: CGEH) - Pacifica Silver Corp. (OTCQB: PAGFF) - BIONXT SOLUTIONS INC. (OTCQB: BNXTF) - Metalsource Mining Inc. (OTCQB: SFRIF) - Orogen Royalties Inc (OTCQB: OGNNF) - SUPERQ QUANTUM COMPUTING INC (OTCQB: QBTQF) - WESTERN STAR RES INC. (OTCQB: WSRIF) - Top End Energy Limited (OTCQB: SERPY, TNDEF) - Hamak Gold Limited (OTCQB: HASTF) - IMA TECH (OTCQB: IMAA) - TOKENWELL PLATFORMS INC. (OTCQB: TWELF) - Crypto Blockchain Industries, SA (OTCQB: CBIPF) - GREENLAND RES INC. (OTCQB: GRLRF) - Nexcel Metals Corp. (OTCQB: NXXCF) - Atex Resources Inc. (OTCQB: ATXRF) - Longevity Health Holdings, Inc. (OTCQB: XAGE) - PRINCE SILVER CORP (OTCQB: PRNCF) - Grayscale Near Trust (OTCQB: GSNR) - ConnectM Technology Solutions, Inc. (OTCQB: CNTM) - Eco Bright Future, Inc. (OTCQB: EBFI) - dMY Squared Technology Group, Inc. (OTCQB: DMYY, DMYYW) [1] Companies Transitioning to Main Board - Sono Group N.V. transitioned to NASDAQ with the ticker SSM on September 5, 2025, focusing on solar technology development and applications [2] - Sol Strategies, Inc. transitioned to NASDAQ with the ticker STKE on September 9, 2025, specializing in Solana blockchain infrastructure [3] - Spruce Biosciences, Inc. transitioned to NASDAQ with the ticker SPRB on September 15, 2025, focusing on innovative therapies for rare endocrine diseases [7] - Grayscale transitioned to NYSE MKT with the ticker GDLC on September 19, 2025, as a multi-asset cryptocurrency fund [8] - BTQ Technologies Corp. transitioned to NASDAQ with the ticker BTQ on September 26, 2025, focusing on quantum computing and cybersecurity [8]

Core Points - NLS Pharmaceutics Ltd. and Kadimastem Ltd. have received Nasdaq approval for the listing of the combined company's shares following the completion of their merger, set to close on October 30, 2025 [1][11] - The final exchange ratio for the merger is established at 7.06 NLS common shares for each Kadimastem ordinary share, which will adjust to 0.706 NLS common shares per Kadimastem ordinary share after a reverse share split [3] - The new entity will be named NewCelX Ltd. and will begin trading on the Nasdaq Capital Market under the ticker symbol "NCEL" starting October 31, 2025 [3] Company Information - NLS Pharmaceutics Ltd. is a Swiss-based biopharmaceutical company focused on developing innovative therapies for central nervous system disorders [5] - Kadimastem Ltd. is a clinical-stage cell therapy company that develops allogeneic, "off-the-shelf" cell products for neurodegenerative diseases and diabetes [6] Shareholder Information - Trading in Kadimastem's ordinary shares on the Tel Aviv Stock Exchange will be suspended until the shares are delisted upon merger completion, with final delisting scheduled for October 31, 2025 [2] - NewCelX common shares are expected to be deposited into Kadimastem shareholders' accounts by the end of the trading day on November 3, 2025, with trading expected to commence on November 4, 2025 [4]

INCHEON, Korea--(BUSINESS WIRE)-- #BYOOVIZ--Samsung Bioepis Co., Ltd. announced today that the company has entered into an Asset Purchase Agreement (APA) with Biogen regarding Samsung Bioepis' two ophthalmology assets: BYOOVIZ® (ranibizumab), a biosimilar referencing Lucentisi (ranibizumab) and OPUVIZ™ (aflibercept), a biosimilar referencing Eyleaii (aflibercept) — in Europe. Samsung Bioepis will have full responsibility for commercialization of BYOOVIZ upon the transfer of commercial rights from Biogen b. ...

Core Insights - The independent Data Safety Monitoring Board (DSMB) has recommended the continuation of the Phase I clinical trial of HG-CT-1, a proprietary CAR-T therapy for relapsed or refractory acute myeloid leukemia (R/R AML) in adults, allowing for escalation to the next dose level [1] - Initial safety assessments for the first three patients treated at the lowest dose level showed no dose-limiting toxicities, indicating a positive safety profile for the therapy [1] Company Developments - Hemogenyx Pharmaceuticals plc has received clearance from the DSMB to proceed with the next dose level in its ongoing clinical trial [1] - The company is now opening recruitment for pediatric patients as part of the trial expansion [1] - The DSMB's recommendation is based on the successful safety data from the initial cohort of patients [1]

Core Insights - Roche has received CE mark for its Elecsys® Dengue Ag test, which is a fully automated immunoassay aimed at diagnosing acute dengue virus infections, setting a new standard for efficiency and reliability in addressing dengue fever [1][3]. Industry Overview - Dengue fever is the most prevalent mosquito-borne viral illness globally, with over 14.6 million cases and more than 12,000 related deaths reported in 2024, marking a historic high [2][11]. - The disease's rapid spread has become a significant global health threat, with half of the world's population now living in areas at risk of infection [2][11]. Product Details - The Elecsys Dengue Ag test detects the NS1 antigen of the dengue virus in human serum and plasma, crucial for early diagnosis during the initial days of illness [4]. - The test has demonstrated 94.90% sensitivity and 99.96% specificity in clinical studies, effectively detecting all four dengue virus serotypes [5]. Key Benefits - The Elecsys Dengue Ag test provides reliable results in just 18 minutes, with a throughput of 120 to 300 tests per hour, enhancing patient management during outbreaks [6][8]. - The automated nature of the test improves laboratory efficiency and reduces the risk of human error, supporting healthcare systems in managing dengue cases [7][8]. Comprehensive Diagnostic Approach - The Elecsys Dengue Panel includes the Elecsys Dengue Ag test, along with IgM and IgG tests, providing a comprehensive diagnostic tool for clinicians to accurately diagnose dengue at various stages of the disease [9].